RU2016128400A - Фармацевтические композиции спиро-оксиндольного соединения для местного введения и их применение в качестве терапевтических агентов - Google Patents
Фармацевтические композиции спиро-оксиндольного соединения для местного введения и их применение в качестве терапевтических агентов Download PDFInfo
- Publication number
- RU2016128400A RU2016128400A RU2016128400A RU2016128400A RU2016128400A RU 2016128400 A RU2016128400 A RU 2016128400A RU 2016128400 A RU2016128400 A RU 2016128400A RU 2016128400 A RU2016128400 A RU 2016128400A RU 2016128400 A RU2016128400 A RU 2016128400A
- Authority
- RU
- Russia
- Prior art keywords
- concentration
- pain
- peg
- pharmaceutical composition
- spiro
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (14)
1. Фармацевтическая композиция для местного введения млекопитающему, содержащая терапевтически эффективное количество спиро-оксиндольного соединения, имеющего следующую формулу:
где спиро-оксиндольное соединение присутствует при концентрации от приблизительно 1% вес./вес. до приблизительно 8% вес./вес.; и растворитель, агент, улучшающий проникновение, загуститель и мазевую основу, где растворитель выбирают из PEG 400 или PEG 3350, агент, улучшающий проникновение, выбирают из Transcutol® P, олеинового спирта или изопропилмиристата, загуститель представляет собой стеариловый спирт, мазевую основу выбирают из PEG 400 или PEG 3350.
2. Фармацевтическая композиция по п.1, в которой PEG 400 присутствует при концентрации от приблизительно 46,9% вес./вес. до приблизительно 53,9% вес./вес., Transcutol® P присутствует при концентрации от приблизительно 5% вес./вес. до приблизительно 10% вес./вес., олеиновый спирт присутствует при концентрации приблизительно 5% вес./вес., изопропилмиристат присутствует при концентрации приблизительно 5% вес./вес., стеариловый спирт присутствует при концентрации от приблизительно 5% вес./вес. до приблизительно 10% вес./вес., и PEG 3350 присутствует при концентрации приблизительно 20% вес./вес.
3. Фармацевтическая композиция по п.2, в которой спиро-оксиндольное соединение присутствует при концентрации от приблизительно 2% вес./вес. до приблизительно 8% вес./вес.
4. Фармацевтическая композиция по п.1, содержащая спиро-оксиндольное соединение при концентрации 2,0% вес./вес.; PEG 400 при концентрации 52,9% вес./вес.; Transcutol® P при концентрации 10% вес./вес.; олеиновый спирт при концентрации 5% вес./вес.; изопропилмиристат при концентрации 5% вес./вес.; стеариловый спирт при концентрации 5% вес./вес.; и PEG 3350 при концентрации 20% вес./вес. фармацевтической композиции.
5. Фармацевтическая композиция по п.1, содержащая спиро-оксиндольное соединение при концентрации 4% вес./вес.; PEG 400 при концентрации 50,9% вес./вес.; Transcutol® P при концентрации 10% вес./вес.; олеиновый спирт при концентрации 5% вес./вес.; изопропилмиристат при концентрации 5% вес./вес.; стеариловый спирт при концентрации 5% вес./вес.; и PEG 3350 при концентрации 20% вес./вес. фармацевтической композиции.
6. Фармацевтическая композиция по п.1, содержащая спиро-оксиндольное соединение при концентрации 4% вес./вес.; PEG 400 при концентрации 50,9% вес./вес.; Transcutol® P при концентрации 5% вес./вес.; олеиновый спирт при концентрации 5% вес./вес.; изопропилмиристат при концентрации 5% вес./вес.; стеариловый спирт при концентрации 10% вес./вес.; и PEG 3350 при концентрации 20% вес./вес. фармацевтической композиции.
7. Фармацевтическая композиция по п.1, содержащая спиро-оксиндольное соединение при концентрации 8% вес./вес.; PEG 400 при концентрации 46,9% вес./вес.; Transcutol® P при концентрации 10% вес./вес.; олеиновый спирт при концентрации 5% вес./вес.; изопропилмиристат при концентрации 5% вес./вес.; стеариловый спирт при концентрации 5% вес./вес.; и PEG 3350 при концентрации 20% вес./вес. фармацевтической композиции.
8. Способ лечения, предотвращения или улучшения заболевания или состояния, опосредованного натриевыми каналами, у млекопитающего, включающий местное введение нуждающемуся в лечении млекопитающему терапевтически эффективного количества фармацевтической композиции по п.1.
9. Способ по п.8, в котором заболевание или состояние выбрано из группы, состоящей из невропатической боли, воспалительной боли, висцеральной боли, постгерпетической невралгии, боли при раке, боли при химиотерапии, боли в результате травмы, операционной боли, постоперационной боли, прурита, остеоартрита, невралгии тройничного нерва, семейной эритромелалгии, первичной эритромелалгии, семейной ректальной боли, боли при родах, боли при родовых схватках, нейрогенного мочевого пузыря, язвенного колита, хронической боли, постоянной боли, периферически опосредованной боли, центрально опосредованной боли, хронической головной боли, мигрени, синусовой головной боли, головной боли напряжения, фантомной боли конечностей, травмы периферических нервов и их комбинаций.
10. Способ по п.8, в котором млекопитающим является человек.
11. Способ лечения боли за счет ингибирования ионного тока через потенциал-зависимые натриевые каналы у млекопитающего, включающий местное введение нуждающемуся в лечении млекопитающему терапевтически эффективного количества фармацевтической композиции по п.1.
12. Способ по п.11, в котором млекопитающим является человек.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30875910P | 2010-02-26 | 2010-02-26 | |
| US61/308,759 | 2010-02-26 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012140955/15A Division RU2596488C2 (ru) | 2010-02-26 | 2011-02-25 | Фармацевтические композиции спиро-оксиндольного соединения для местного введения и их применение в качестве терапевтических агентов |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2016128400A true RU2016128400A (ru) | 2018-12-06 |
Family
ID=43981337
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012140955/15A RU2596488C2 (ru) | 2010-02-26 | 2011-02-25 | Фармацевтические композиции спиро-оксиндольного соединения для местного введения и их применение в качестве терапевтических агентов |
| RU2016128400A RU2016128400A (ru) | 2010-02-26 | 2011-02-25 | Фармацевтические композиции спиро-оксиндольного соединения для местного введения и их применение в качестве терапевтических агентов |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012140955/15A RU2596488C2 (ru) | 2010-02-26 | 2011-02-25 | Фармацевтические композиции спиро-оксиндольного соединения для местного введения и их применение в качестве терапевтических агентов |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US9504671B2 (ru) |
| EP (2) | EP3266444A1 (ru) |
| JP (2) | JP2013521232A (ru) |
| KR (1) | KR20120131162A (ru) |
| CN (2) | CN105726531A (ru) |
| AU (2) | AU2011220396B2 (ru) |
| BR (1) | BR112012021086A2 (ru) |
| CA (1) | CA2788440A1 (ru) |
| CL (1) | CL2012002126A1 (ru) |
| CO (1) | CO6571900A2 (ru) |
| EC (1) | ECSP12012171A (ru) |
| HK (1) | HK1182619A1 (ru) |
| HR (1) | HRP20120740A2 (ru) |
| IL (1) | IL221646A (ru) |
| MA (1) | MA34083B1 (ru) |
| MX (1) | MX343215B (ru) |
| MY (1) | MY165117A (ru) |
| NZ (1) | NZ601667A (ru) |
| PE (1) | PE20121699A1 (ru) |
| RU (2) | RU2596488C2 (ru) |
| SG (1) | SG183126A1 (ru) |
| TN (1) | TN2012000421A1 (ru) |
| WO (1) | WO2011106729A2 (ru) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY144968A (en) | 2005-04-11 | 2011-11-30 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds and their uses as therapeutic agents |
| PL1888548T3 (pl) | 2005-05-26 | 2013-01-31 | Neuron Systems Inc | Pochodna chinoliny do leczenia schorzeń siatkówki |
| EP2073806B1 (en) | 2006-10-12 | 2012-02-15 | Xenon Pharmaceuticals Inc. | Use of spiro-oxindole compounds as therapeutic agents |
| CN106928247A (zh) | 2008-10-17 | 2017-07-07 | 泽农医药公司 | 螺羟吲哚化合物及其作为治疗剂的用途 |
| AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
| PE20170202A1 (es) | 2009-10-14 | 2017-03-24 | Xenon Pharmaceuticals Inc | Metodos sinteticos para compuestos espiro-oxoindol |
| CA2782015C (en) | 2009-12-11 | 2020-08-25 | Neuron Systems, Inc. | Topical ophthalmic compositions and methods for the treatment of macular degeneration |
| JP5765965B2 (ja) | 2010-02-26 | 2015-08-19 | 日本たばこ産業株式会社 | １，３，４，８−テトラヒドロ−２Ｈ−ピリド［１，２−ａ］ピラジン誘導体及びそのＨＩＶインテグラーゼ阻害剤としての利用 |
| MA34083B1 (fr) | 2010-02-26 | 2013-03-05 | Xenon Pharmaceuticals Inc | Compositions pharmaceutques de composé spiro-oxindole pour administration topique et leur utilisation en tant qu'agents thérapeutiques |
| US9487535B2 (en) | 2012-04-12 | 2016-11-08 | Xenon Pharmaceuticals Inc. | Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents |
| GB201312295D0 (en) * | 2013-07-09 | 2013-08-21 | Syntaxin Ltd | Suppression of itch |
| UY35981A (es) | 2014-02-05 | 2015-08-31 | Ivax Int Gmbh | Métodos para tratar el dolor asociado a la osteoartritis en una articulación con una formulación tópica de un compuesto de espirooxindol |
| US9682033B2 (en) | 2015-02-05 | 2017-06-20 | Teva Pharmaceuticals International Gmbh | Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound |
| WO2016133967A2 (en) * | 2015-02-18 | 2016-08-25 | Parion Sciences, Inc. | Sodium channel blockers for skin disorders |
| KR20180095598A (ko) | 2015-12-18 | 2018-08-27 | 머크 샤프 앤드 돔 코포레이션 | 전압-게이팅 나트륨 채널에서 선택적 활성을 갖는 히드록시알킬아민- 및 히드록시시클로알킬아민-치환된 디아민-아릴술폰아미드 화합물 |
| JP2019518058A (ja) | 2016-06-16 | 2019-06-27 | ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | スピロ−オキシインドール化合物の固体状態形 |
| WO2017218920A1 (en) | 2016-06-16 | 2017-12-21 | Teva Pharmaceuticals International Gmbh | Asymmetric synthesis of funapide |
| CA3077362A1 (en) | 2017-10-10 | 2019-04-18 | Aldeyra Therapeutics, Inc. | Treatment of inflammatory disorders |
| CN112040948A (zh) * | 2018-03-29 | 2020-12-04 | 顺天医药生技股份有限公司 | 治疗瘙痒的组合物和方法 |
| JP2019206497A (ja) * | 2018-05-30 | 2019-12-05 | 小林製薬株式会社 | 外用医薬組成物 |
| WO2020028820A1 (en) * | 2018-08-03 | 2020-02-06 | Aldeyra Therapeutics, Inc. | Topical compositions and methods of preparation and use |
| US12006298B2 (en) | 2018-08-06 | 2024-06-11 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| JP7505786B2 (ja) | 2018-09-25 | 2024-06-25 | アルデイラ セラピューティクス， インコーポレイテッド | ドライアイ疾患を処置するための製剤 |
| WO2020198064A1 (en) | 2019-03-26 | 2020-10-01 | Aldeyra Therapeutics, Inc. | Ophthalmic formulations and uses thereof |
| CA3137301A1 (en) | 2019-05-02 | 2020-11-05 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| US12098132B2 (en) | 2019-05-02 | 2024-09-24 | Aldeyra Therapeutics, Inc. | Process for preparation of aldehyde scavenger and intermediates |
| EP4027979A4 (en) * | 2019-09-09 | 2023-10-04 | Pacira Therapeutics, Inc. | SUSTAINED RELEASE HEAT CURING GELS WITH SODIUM CHANNEL BLOCKERS AND METHOD FOR THE PRODUCTION THEREOF |
| EP4149470A4 (en) | 2020-05-13 | 2024-04-24 | Aldeyra Therapeutics, Inc. | PHARMACEUTICAL FORMULATIONS AND USES THEREOF |
Family Cites Families (147)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US614969A (en) | 1898-11-29 | murphy | ||
| US3189617A (en) | 1961-02-03 | 1965-06-15 | Sterling Drug Inc | 1-aryloxindoles and their preparation |
| DE1956237A1 (de) | 1969-11-08 | 1971-05-13 | Basf Ag | Spiro-pyrrolizidon-oxindole |
| DE2113343A1 (de) | 1971-03-19 | 1972-09-21 | Thiemann Chem Pharm Fab | Indolo[2,3-b] chinolone und Verfahren zu ihrer Herstellung |
| US3723459A (en) | 1971-04-23 | 1973-03-27 | Mc Neil Labor Inc | 2-oxospiro (indoline -3,4{40 -thiochroman) derivatives |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| SE400966B (sv) | 1975-08-13 | 1978-04-17 | Robins Co Inc A H | Forfarande for framstellning av 2-amino-3-(eller 5-)bensoyl-fenylettiksyror |
| US4670566A (en) | 1979-07-12 | 1987-06-02 | A. H. Robins Company, Incorporated | 3-methyl-hio-4-(5-, 6-, or 7-)phenylindolindolin-2-ones |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US4440785A (en) | 1980-10-30 | 1984-04-03 | A. H. Robins Company, Inc. | Methods of using 2-aminobiphenylacetic acids, esters, and metal salts thereof to treat inflammation |
| US4438130A (en) | 1981-11-12 | 1984-03-20 | The Upjohn Company | Analgesic 1-oxa-, aza- and thia-spirocyclic compounds |
| JPS60142984A (ja) | 1983-12-28 | 1985-07-29 | Kyorin Pharmaceut Co Ltd | 新規なスピロピロリジン−２，５−ジオン誘導体およびその製造法 |
| US4569942A (en) | 1984-05-04 | 1986-02-11 | Pfizer Inc. | N,3-Disubstituted 2-oxindole-1-carboxamides as analgesic and antiinflammatory agents |
| JPS6130554A (ja) | 1984-07-23 | 1986-02-12 | Ono Pharmaceut Co Ltd | プロスタグランジン類似化合物のある特定の立体配置を有する異性体及びそれらを有効成分として含有する治療剤 |
| US4690943A (en) | 1984-09-19 | 1987-09-01 | Pfizer Inc. | Analgesic and antiinflammatory 1,3-diacyl-2-oxindole compounds |
| US4721721A (en) | 1984-12-18 | 1988-01-26 | Rorer Pharmaceutical Corporation | 6-(4-thiazole) compounds, cardiotonic compositions including the same, and their uses |
| DE3608088C2 (de) | 1986-03-07 | 1995-11-16 | Schering Ag | Pharmazeutische Präparate, enthaltend Cyclodextrinclathrate von Carbacyclinderivaten |
| WO1993012786A1 (en) | 1986-07-10 | 1993-07-08 | Howard Harry R Jr | Indolinone derivatives |
| ES2054860T5 (es) | 1987-07-17 | 2003-11-01 | Schering Ag | Derivados de 9-halogeno-(z)-prostaglandinas, procedimiento para su preparacion y su utilizacion como medicamentos. |
| US5182289A (en) | 1988-06-14 | 1993-01-26 | Schering Corporation | Heterobicyclic compounds having antiinflammatory activity |
| ES2110965T3 (es) | 1989-07-25 | 1998-03-01 | Taiho Pharmaceutical Co Ltd | Derivado de oxoindol. |
| DE3932953A1 (de) | 1989-10-03 | 1991-04-11 | Boehringer Mannheim Gmbh | Neue 2-bicyclo-benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| DE3935514A1 (de) | 1989-10-25 | 1991-05-02 | Boehringer Mannheim Gmbh | Neue bicyclo-imidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5023265A (en) | 1990-06-01 | 1991-06-11 | Schering Corporation | Substituted 1-H-pyrrolopyridine-3-carboxamides |
| US5484778C1 (en) | 1990-07-17 | 2001-05-08 | Univ Cleveland Hospitals | Phthalocynine photosensitizers for photodynamic therapy and methods for their use |
| EP0558521A1 (en) | 1990-11-22 | 1993-09-08 | Janssen Pharmaceutica N.V. | Isonicotinic acid derivatives and related spiro compounds with herbicidal action |
| US5116854A (en) | 1991-06-28 | 1992-05-26 | Pfizer Inc. | Anti-inflammatory 1-heteroaryl-3-acyl-2-oxindoles |
| FR2686878B1 (fr) | 1992-01-30 | 1995-06-30 | Sanofi Elf | Derives du n-sulfonyl oxo-2 indole, leur preparation, les compositions pharmaceutiques en contenant. |
| US5663431A (en) | 1992-01-30 | 1997-09-02 | Sanofi | 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present |
| US5686624A (en) | 1992-01-30 | 1997-11-11 | Sanofi | 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present |
| US5849780A (en) | 1992-01-30 | 1998-12-15 | Sanofi | 1-benzenesulfonyl-1-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present |
| FR2708605A1 (fr) | 1993-07-30 | 1995-02-10 | Sanofi Sa | Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant. |
| US5314685A (en) | 1992-05-11 | 1994-05-24 | Agouron Pharmaceuticals, Inc. | Anhydrous formulations for administering lipophilic agents |
| AU672224B2 (en) | 1992-08-06 | 1996-09-26 | Warner-Lambert Company | 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and whichhave antitumor properties |
| US5278162A (en) | 1992-09-18 | 1994-01-11 | The Du Pont Merck Pharmaceutical Company | 3,3'-disubstituted-1,3-dihydro-2H-pyrrolo[2,3-b]heterocyclic-2-one useful in the treatment of cognitive disorders of man |
| US5296478A (en) | 1992-10-07 | 1994-03-22 | The Dupont Merck Pharmaceutical Co. | 1-substituted oxindoles as cognition enhancers |
| US5776936A (en) | 1992-11-13 | 1998-07-07 | Pharmacia & Upjohn Company | Marcfortine/paraherquamide derivatives useful as antiparasitic agents |
| DE4242451A1 (de) | 1992-12-16 | 1994-06-23 | Basf Ag | Verfahren zur Herstellung von 5-Ringheterocyclen |
| US5298522A (en) | 1993-01-22 | 1994-03-29 | Pfizer Inc. | 6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide as an analgesic and anti-inflammatory agent while maintaining a normal urine protein/creatinine ratio |
| US5716981A (en) | 1993-07-19 | 1998-02-10 | Angiogenesis Technologies, Inc. | Anti-angiogenic compositions and methods of use |
| FR2708606B1 (fr) | 1993-07-30 | 1995-10-27 | Sanofi Sa | Dérivés du N-phénylalkylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant. |
| US5502072A (en) | 1993-11-26 | 1996-03-26 | Pfizer Inc. | Substituted oxindoles |
| AT400950B (de) | 1994-02-04 | 1996-04-25 | Immodal Pharmaka Gmbh | Verfahren zur technischen herstellung definierter isomerengemische aus verbindungen mit spirozyklischen - aminocarboxyl- und/oder spirozyklischen - aminocarbonyl-systemen |
| WO1995027712A1 (fr) | 1994-04-07 | 1995-10-19 | Cemaf | Nouveaux derives de spiro[indole-pyrrolidine] agonistes melatoninergiques, leur procede de preparation et leur utilisation a titre de medicament |
| US5618819A (en) | 1994-07-07 | 1997-04-08 | Adir Et Compagnie | 1,3-dihydro-2H-pyrrolo[2,3-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-(3H)-one compounds |
| FR2722195B1 (fr) | 1994-07-07 | 1996-08-23 | Adir | Nouveaux derives de 1,3-dihydro-2h-pyrrolo(2,3-b) pyridin-2-ones et oxazolo(4,5-b) pyridin-2(3h)-ones, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| WO1996019477A1 (en) | 1994-12-22 | 1996-06-27 | Smithkline Beecham Plc | Tetracyclic spiro compounds, process for their preparation and their use as 5ht1d receptor antagonists |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| FR2740136B1 (fr) | 1995-10-24 | 1998-01-09 | Sanofi Sa | Derives d'indolin-2-one, procede pour leur preparation et les compositions pharmaceutiques les contenant |
| CA2235686C (en) | 1995-10-24 | 2007-06-26 | Sanofi | Indolin-2-one derivatives, process for their production and the pharmaceutical compositions containing them |
| HUP9600855A3 (en) | 1996-04-03 | 1998-04-28 | Egyt Gyogyszervegyeszeti Gyar | Process for producing tenidap |
| FR2757157B1 (fr) | 1996-12-13 | 1999-12-31 | Sanofi Sa | Derives d'indolin-2-one, procede pour leur preparation et compositions pharmaceutiques les contenant |
| ATE467418T1 (de) | 1997-01-20 | 2010-05-15 | Immodal Pharmaka Gmbh | Verfahren und stoffe zur freisetzung eines wachstumsfaktors aus endothelzellen, und nach dem verfahren freigesetzter wachstumsfaktor sowie seine verwendung |
| NO317155B1 (no) | 1997-02-04 | 2004-08-30 | Ono Pharmaceutical Co | <omega>-cykloalkyl-prostagladin-E<N>2</N>-derivater |
| DK1008588T3 (da) | 1997-02-10 | 2003-07-28 | Ono Pharmaceutical Co | 11,15-O-dialkylprostaglandin E derivater, fremgangsmåder til fremstilling deraf og farmaceutiske sammensætninger, der omfatter dem som virksom bestanddel |
| IL132702A0 (en) | 1997-05-07 | 2001-03-19 | Galen Chemicals Ltd | Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors |
| DE69821987T2 (de) | 1997-12-25 | 2004-12-16 | Ono Pharmaceutical Co. Ltd. | Omega-cycloalkyl-prostaglandin e2 derivate |
| JP4087938B2 (ja) | 1998-02-04 | 2008-05-21 | 高砂香料工業株式会社 | ヒノキチオ−ル類の分岐サイクロデキストリン包接化合物からなる抗菌剤およびそれを含有する組成物 |
| ES2217742T3 (es) | 1998-04-01 | 2004-11-01 | Cardiome Pharma Corp. | Compuestos de amino ciclohexil eter y usos del mismo. |
| US20040038970A1 (en) | 1998-06-12 | 2004-02-26 | Societe De Conseils De Recherches Etd' Application Scientifiques, S.A.S. A Paris, France Corp. | Beta-carboline compounds |
| US6235780B1 (en) | 1998-07-21 | 2001-05-22 | Ono Pharmaceutical Co., Ltd. | ω-cycloalkyl-prostaglandin E1 derivatives |
| WO2000006556A1 (en) | 1998-07-27 | 2000-02-10 | Abbott Laboratories | Substituted oxazolines as antiproliferative agents |
| SE9900100D0 (sv) | 1999-01-15 | 1999-01-15 | Astra Ab | New compounds |
| US6407101B1 (en) | 1999-05-04 | 2002-06-18 | American Home Products Corporation | Cyanopyrroles |
| US6355648B1 (en) | 1999-05-04 | 2002-03-12 | American Home Products Corporation | Thio-oxindole derivatives |
| MXPA01011832A (es) | 1999-05-21 | 2002-06-21 | Squibb Bristol Myers Co | Inhibidores de cinasas, de pirrolotriazina. |
| JP3833532B2 (ja) | 1999-07-21 | 2006-10-11 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 炎症性疾患の治療において有用な小分子 |
| EP1202994B1 (en) | 1999-07-21 | 2004-04-14 | AstraZeneca AB | New compounds |
| US6566372B1 (en) | 1999-08-27 | 2003-05-20 | Ligand Pharmaceuticals Incorporated | Bicyclic androgen and progesterone receptor modulator compounds and methods |
| WO2001038564A2 (en) | 1999-11-26 | 2001-05-31 | Mcgill University | Loci for idiopathic generalized epilepsy, mutations thereof and method using same to assess, diagnose, prognose or treat epilepsy |
| FR2807038B1 (fr) | 2000-04-03 | 2002-08-16 | Sanofi Synthelabo | Nouveaux derives d'indolin-2-one, leur preparation et les compositions pharmaceutiques les contenant |
| AU2002213204A1 (en) | 2000-10-13 | 2002-04-22 | Bristol-Myers Squibb Company | Selective maxi-K- potassium channel openers functional under conditions of high intracellular calcium concentration, methods and uses thereof |
| US6825220B2 (en) | 2000-11-10 | 2004-11-30 | Eli Lilly And Company | 3-Substituted oxindole β 3 agonists |
| US6670357B2 (en) | 2000-11-17 | 2003-12-30 | Bristol-Myers Squibb Company | Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors |
| US20030078278A1 (en) | 2001-06-26 | 2003-04-24 | Pfizer Inc. | Spiropiperidine compounds as ligands for ORL-1 receptor |
| DE60211199T2 (de) | 2001-08-14 | 2007-02-01 | Eli Lilly And Co., Indianapolis | 3-substituierte oxindol-beta-3-agonisten |
| CA2465328C (en) | 2001-11-01 | 2011-06-14 | Michael Francis Gross | Piperidines |
| ES2338539T3 (es) | 2001-11-01 | 2010-05-10 | Icagen, Inc. | Pirazolamidas para uso en el tratamiento del dolor. |
| JP2005514366A (ja) | 2001-11-20 | 2005-05-19 | イーライ・リリー・アンド・カンパニー | ３−置換オキシインドールβ３アゴニスト |
| SE0104341D0 (sv) | 2001-12-20 | 2001-12-20 | Astrazeneca Ab | New use |
| EP1470126A1 (en) | 2002-01-28 | 2004-10-27 | Pfizer Inc. | N-substituted spiropiperidine compounds as ligands for orl-1 receptor |
| US6995144B2 (en) | 2002-03-14 | 2006-02-07 | Eisai Co., Ltd. | Nitrogen containing heterocyclic compounds and medicines containing the same |
| JP2006508893A (ja) | 2002-03-15 | 2006-03-16 | イーライ・リリー・アンド・カンパニー | ステロイドホルモン核内レセプターモジュレーターとしてのジヒドロインドール−２−オン誘導体 |
| US7595311B2 (en) | 2002-05-24 | 2009-09-29 | Exelixis, Inc. | Azepinoindole derivatives as pharmaceutical agents |
| GB0213715D0 (en) | 2002-06-14 | 2002-07-24 | Syngenta Ltd | Chemical compounds |
| IL165395A0 (en) | 2002-06-25 | 2006-01-15 | Wyeth Corp | Use of thio-oxubdile derivatives in treatment of hormone-related conditions |
| JP2005535625A (ja) | 2002-06-25 | 2005-11-24 | ワイス | 皮膚障害の治療におけるチオオキシインドール誘導体の使用 |
| US7256218B2 (en) | 2002-11-22 | 2007-08-14 | Jacobus Pharmaceutical Company, Inc. | Biguanide and dihydrotriazine derivatives |
| KR20130066701A (ko) | 2003-02-24 | 2013-06-20 | 미쓰비시 타나베 파마 코퍼레이션 | 테나토프라졸의 거울상 이성질체 및 치료를 위한 그 용도 |
| JP2007516955A (ja) | 2003-05-16 | 2007-06-28 | ファイザー・プロダクツ・インク | 双極性障害および関連症候の治療 |
| EP1633361A1 (en) | 2003-05-16 | 2006-03-15 | Pfizer Products Inc. | Anxiety treatments with ziprasidone |
| EP1633360A1 (en) | 2003-05-16 | 2006-03-15 | Pfizer Products Incorporated | Treatment of psychotic and depressive disorders |
| CA2625837A1 (en) | 2003-05-16 | 2004-11-25 | Pfizer Products Inc. | Method for enhancing cognition using ziprasidone |
| BRPI0412348A (pt) | 2003-07-30 | 2006-09-05 | Xenon Pharmaceuticals Inc | derivados de piperazina e seu uso como agentes terapêuticos |
| DE10337184A1 (de) | 2003-08-13 | 2005-03-10 | Gruenenthal Gmbh | Substituierte 3-Pyrrolidin-Indol-Derivate |
| WO2005016913A1 (en) | 2003-08-19 | 2005-02-24 | Pfizer Japan, Inc. | Tetrahydroisoquinoline or isochroman compounds as orl-1 receptor ligands for the treatment of pain and cns disorders |
| WO2005035498A1 (ja) | 2003-10-08 | 2005-04-21 | Dainippon Sumitomo Pharma Co., Ltd. | 含窒素二環性化合物の摂食調節剤としての用途 |
| EP1557166A1 (en) | 2004-01-21 | 2005-07-27 | Newron Pharmaceuticals S.p.A. | Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders |
| US7507760B2 (en) | 2004-01-22 | 2009-03-24 | Neuromed Pharmaceuticals Ltd. | N-type calcium channel blockers |
| GB0406867D0 (en) | 2004-03-26 | 2004-04-28 | F2G Ltd | Antifungal agents |
| WO2005097136A1 (en) | 2004-03-29 | 2005-10-20 | Merck & Co., Inc. | Biaryl substituted pyrazinones as sodium channel blockers |
| WO2005092858A2 (en) | 2004-03-29 | 2005-10-06 | Pfizer Japan Inc. | Alpha aryl or heteroaryl methyl beta piperidino propanamide compounds as orl1-receptor antagonist |
| WO2005099689A1 (en) | 2004-04-01 | 2005-10-27 | Case Western Reserve University | Topical delivery of phthalocyanines |
| GT200500063A (es) | 2004-04-01 | 2005-10-14 | Metodo para tratar la esquizofrenia y/o anormalidades glucoregulatorias | |
| US20070299102A1 (en) | 2004-04-08 | 2007-12-27 | Topo Target A/S | Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer |
| AU2005237520B2 (en) | 2004-04-27 | 2012-01-19 | Wyeth | Purification of progesterone receptor modulators |
| JP2007536283A (ja) | 2004-05-05 | 2007-12-13 | ユニバイオスクリーン エス．アー． | ナフタルイミド誘導体、それらの製造方法、およびそれらの医薬組成物 |
| TWI350168B (en) | 2004-05-07 | 2011-10-11 | Incyte Corp | Amido compounds and their use as pharmaceuticals |
| MXPA06011658A (es) | 2004-05-14 | 2006-12-14 | Pfizer Prod Inc | Derivados de pirimidina para el tratamiento del crecimiento celular anormal. |
| AU2005267331A1 (en) | 2004-06-24 | 2006-02-02 | Incyte Corporation | Amido compounds and their use as pharmaceuticals |
| GT200500186A (es) | 2004-07-07 | 2006-03-02 | Regimenes anticonceptivos con antagonistas del receptor de progesterona y kits | |
| GT200500185A (es) | 2004-08-09 | 2006-04-10 | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos | |
| GT200500183A (es) | 2004-08-09 | 2006-04-10 | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos | |
| JP4677323B2 (ja) | 2004-11-01 | 2011-04-27 | キヤノン株式会社 | 画像処理装置及び画像処理方法 |
| MX2007005820A (es) | 2004-11-18 | 2007-07-18 | Incyte Corp | Inhibidores de deshidrogenasa esteroide hidroxilo 11-beta tipo 1 y metodos de uso de los mismos. |
| DE102005007694A1 (de) | 2005-02-18 | 2006-09-21 | Henkel Kgaa | Mittel zum Färben von keratinhaltigen Fasern |
| MX2007010272A (es) | 2005-02-22 | 2008-03-12 | Univ Michigan | Inhibidores de moleculas pequenas de mdm2 y usos de los mismos. |
| MY145694A (en) | 2005-04-11 | 2012-03-30 | Xenon Pharmaceuticals Inc | Spiroheterocyclic compounds and their uses as therapeutic agents |
| MY144968A (en) | 2005-04-11 | 2011-11-30 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds and their uses as therapeutic agents |
| AR053713A1 (es) | 2005-04-20 | 2007-05-16 | Xenon Pharmaceuticals Inc | Compuestos heterociclicos y sus usos como agentes terapeuticos |
| AR056317A1 (es) | 2005-04-20 | 2007-10-03 | Xenon Pharmaceuticals Inc | Compuestos de oxindol y composicion farmaceutica |
| WO2006118955A2 (en) | 2005-04-29 | 2006-11-09 | Wyeth | Process for preparing 3,3-disubstituted oxindoles and thio-oxindoles |
| AR057023A1 (es) | 2005-05-16 | 2007-11-14 | Gilead Sciences Inc | Compuestos heterociclicos con propiedades inhibidoras de hiv-integrasa |
| DK1924264T5 (en) | 2005-09-01 | 2014-03-24 | Hoffmann La Roche | Diaminopyrimidines as P2X3- and P2X2 / 3 modulators |
| AU2007258675A1 (en) | 2006-06-09 | 2007-12-21 | Merck Sharp & Dohme Corp. | Benzazepinones as sodium channel blockers |
| US20110237567A9 (en) | 2006-10-12 | 2011-09-29 | Xenon Pharmaceuticals Inc. | Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents |
| WO2008046083A2 (en) | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Use of oxindole compounds as therapeutic agents |
| WO2008046087A2 (en) | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Spiro compounds and their uses as therapeutic agents |
| EP2073806B1 (en) * | 2006-10-12 | 2012-02-15 | Xenon Pharmaceuticals Inc. | Use of spiro-oxindole compounds as therapeutic agents |
| WO2008046084A2 (en) | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Spiroheterocyclic compounds and their uses as therapeutic agents |
| AR063277A1 (es) | 2006-10-12 | 2009-01-14 | Xenon Pharmaceuticals Inc | Compuestos espiroheterociclicos y usos como agentes terapeuticos |
| US20110294842A9 (en) | 2006-10-12 | 2011-12-01 | Xenon Pharmaceuticals Inc. | Spiro (furo [3, 2-c] pyridine-3-3' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain |
| WO2008046082A2 (en) | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Use of heterocyclic compounds as therapeutic agents |
| GB0704846D0 (en) | 2007-03-13 | 2007-04-18 | Futura Medical Dev Ltd | Topical pharmaceutical formulation |
| WO2008117050A1 (en) | 2007-03-27 | 2008-10-02 | Astrazeneca Ab | Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer |
| CA2689137C (en) | 2007-05-29 | 2017-05-02 | Intrexon Corporation | Chiral diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
| EP2350091B1 (en) | 2008-10-17 | 2015-06-03 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
| CN106928247A (zh) | 2008-10-17 | 2017-07-07 | 泽农医药公司 | 螺羟吲哚化合物及其作为治疗剂的用途 |
| WO2010053998A1 (en) | 2008-11-05 | 2010-05-14 | Xenon Pharmaceuticals, Inc. | Spiro-condensed indole derivatives as sodium channel inhibitors |
| WO2010078307A1 (en) | 2008-12-29 | 2010-07-08 | Xenon Pharmaceuticals Inc. | Spiro-oxindole-derivatives as sodium channel blockers |
| WO2010132352A2 (en) | 2009-05-11 | 2010-11-18 | Xenon Pharmaceuticals Inc. | Spiro compounds and their use as therapeutic agents |
| AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
| US20110086899A1 (en) | 2009-10-14 | 2011-04-14 | Xenon Pharmaceuticals Inc. | Pharmaceutical compositions for oral administration |
| PE20170202A1 (es) | 2009-10-14 | 2017-03-24 | Xenon Pharmaceuticals Inc | Metodos sinteticos para compuestos espiro-oxoindol |
| MA34083B1 (fr) | 2010-02-26 | 2013-03-05 | Xenon Pharmaceuticals Inc | Compositions pharmaceutques de composé spiro-oxindole pour administration topique et leur utilisation en tant qu'agents thérapeutiques |
| US9487535B2 (en) | 2012-04-12 | 2016-11-08 | Xenon Pharmaceuticals Inc. | Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents |
-
2011
- 2011-02-25 MA MA35240A patent/MA34083B1/fr unknown
- 2011-02-25 RU RU2012140955/15A patent/RU2596488C2/ru not_active IP Right Cessation
- 2011-02-25 CA CA2788440A patent/CA2788440A1/en not_active Abandoned
- 2011-02-25 US US13/580,129 patent/US9504671B2/en active Active
- 2011-02-25 PE PE2012001098A patent/PE20121699A1/es not_active Application Discontinuation
- 2011-02-25 KR KR1020127021645A patent/KR20120131162A/ko not_active Application Discontinuation
- 2011-02-25 AU AU2011220396A patent/AU2011220396B2/en not_active Ceased
- 2011-02-25 EP EP17001087.0A patent/EP3266444A1/en not_active Withdrawn
- 2011-02-25 MX MX2012009838A patent/MX343215B/es active IP Right Grant
- 2011-02-25 MY MYPI2012003812A patent/MY165117A/en unknown
- 2011-02-25 CN CN201610060072.4A patent/CN105726531A/zh active Pending
- 2011-02-25 BR BR112012021086A patent/BR112012021086A2/pt not_active IP Right Cessation
- 2011-02-25 EP EP11707750.3A patent/EP2538919B1/en active Active
- 2011-02-25 SG SG2012056909A patent/SG183126A1/en unknown
- 2011-02-25 WO PCT/US2011/026359 patent/WO2011106729A2/en active Application Filing
- 2011-02-25 CN CN201180010245.7A patent/CN102946859B/zh not_active Expired - Fee Related
- 2011-02-25 NZ NZ601667A patent/NZ601667A/en not_active IP Right Cessation
- 2011-02-25 RU RU2016128400A patent/RU2016128400A/ru not_active Application Discontinuation
- 2011-02-25 JP JP2012555199A patent/JP2013521232A/ja not_active Ceased
-
2012
- 2012-07-30 CO CO12127396A patent/CO6571900A2/es unknown
- 2012-07-31 CL CL2012002126A patent/CL2012002126A1/es unknown
- 2012-08-16 TN TNP2012000421A patent/TN2012000421A1/en unknown
- 2012-08-26 IL IL221646A patent/IL221646A/en not_active IP Right Cessation
- 2012-09-17 HR HRP20120740AA patent/HRP20120740A2/hr not_active Application Discontinuation
- 2012-09-21 EC ECSP12012171 patent/ECSP12012171A/es unknown
-
2013
- 2013-08-23 HK HK13109913.0A patent/HK1182619A1/zh not_active IP Right Cessation
-
2016
- 2016-04-22 JP JP2016085812A patent/JP2016135806A/ja not_active Withdrawn
- 2016-10-11 US US15/290,676 patent/US20170095449A1/en not_active Abandoned
-
2017
- 2017-01-10 AU AU2017200159A patent/AU2017200159A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016128400A (ru) | Фармацевтические композиции спиро-оксиндольного соединения для местного введения и их применение в качестве терапевтических агентов | |
| JP2020519661A5 (ru) | ||
| JP2018505169A5 (ru) | ||
| MA40111A1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
| RU2013141845A (ru) | Фармацевтическая композиция в виде крема, содержащая оксиметазолин, для лечения симптомов розацеа | |
| RU2011129229A (ru) | Новые соли | |
| EA201101671A1 (ru) | Замещенные производные аминопропионовой кислоты в качестве ингибиторов неприлизина | |
| JP2010053135A5 (ru) | ||
| RU2012122241A (ru) | Птеростилбен (pter) для применения в профилактике и/или лечении кожных заболеваний, повреждений или травм | |
| NZ596976A (en) | Sublingual dexmedetomidine compositions and methods of use thereof | |
| JP2012144574A5 (ru) | ||
| EA201001455A1 (ru) | Пиридины и пиразины в качестве ингибиторов pi3k (фосфатидилинозиткиназы-3) | |
| EA201790088A1 (ru) | Ингибиторы syk | |
| BR112013025634A2 (pt) | inibidores de hsp90 | |
| RU2008111494A (ru) | Композиции и способы для улучшения функциональной целостности сосудов, выживания клеток и уменьшения апоптоза при ишемии или после ишемического приступа в мозге | |
| JP2011502174A5 (ru) | ||
| RU2008146816A (ru) | Фармацевтическая комбинация, содержащая 3-(3-диметиламино-1-этил-2-метилпропил)фенол и парацетамол | |
| CA2640569A1 (en) | Inhibiting amyloid-beta peptide/rage interaction at the blood-brain barrier | |
| PE20241127A1 (es) | Compuestos triciclicos como inhibidores de kras | |
| RU2013113184A (ru) | Комбинированное лечение розацеа | |
| JP2013519653A5 (ru) | ||
| RU2018107930A (ru) | Агонисты tlr4, их композиции и применение для лечения рака | |
| RU2009128970A (ru) | Производные изосорбидмононитрата для лечения кишечных заболеваний | |
| RU2015112121A (ru) | Ми-рнк и их применение в способах и композициях для лечения и/или профилактики глазных состояний | |
| JP2005529935A5 (ru) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20190715 |